Investor Relations

Assembly Biosciences (Nasdaq: ASMB) is a biotechnology company developing novel oral therapies for hepatitis B virus (HBV) and C. difficile infections (CDI). Both programs have breakthrough potential to achieve higher cure rates for these debilitating diseases.

Investor Data

© 2016 Assembly Biosciences

Back to top